PL371270A1 - Podstawione pochodne 2-pirolidyn-2-ylo-1H-indolu do zwalczania migreny - Google Patents
Podstawione pochodne 2-pirolidyn-2-ylo-1H-indolu do zwalczania migrenyInfo
- Publication number
- PL371270A1 PL371270A1 PL02371270A PL37127002A PL371270A1 PL 371270 A1 PL371270 A1 PL 371270A1 PL 02371270 A PL02371270 A PL 02371270A PL 37127002 A PL37127002 A PL 37127002A PL 371270 A1 PL371270 A1 PL 371270A1
- Authority
- PL
- Poland
- Prior art keywords
- migraine
- pyrrolidine
- substituted
- treatment
- indole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10159922A DE10159922A1 (de) | 2001-12-06 | 2001-12-06 | Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL371270A1 true PL371270A1 (pl) | 2005-06-13 |
Family
ID=7708242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02371270A PL371270A1 (pl) | 2001-12-06 | 2002-12-02 | Podstawione pochodne 2-pirolidyn-2-ylo-1H-indolu do zwalczania migreny |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7271192B2 (pl) |
| EP (1) | EP1451177B1 (pl) |
| JP (1) | JP4663982B2 (pl) |
| AR (1) | AR037707A1 (pl) |
| AT (1) | ATE357441T1 (pl) |
| AU (1) | AU2002363859B2 (pl) |
| CA (1) | CA2469346C (pl) |
| CY (1) | CY1106576T1 (pl) |
| DE (2) | DE10159922A1 (pl) |
| DK (1) | DK1451177T3 (pl) |
| ES (1) | ES2284973T3 (pl) |
| HU (1) | HUP0402283A3 (pl) |
| MX (1) | MXPA04005139A (pl) |
| PE (1) | PE20030748A1 (pl) |
| PL (1) | PL371270A1 (pl) |
| PT (1) | PT1451177E (pl) |
| SI (1) | SI1451177T1 (pl) |
| WO (1) | WO2003048156A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7851478B2 (en) | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
| AR079528A1 (es) * | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
| US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
| CN112010841A (zh) * | 2020-08-20 | 2020-12-01 | 上海体育学院 | 一种基于吲哚骨架的吡咯烷衍生物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3506683A (en) * | 1963-10-07 | 1970-04-14 | Upjohn Co | 3-(2-pyrrolidinylidene)-3h-indoles |
| KR0184911B1 (ko) * | 1991-11-25 | 1999-05-01 | 알렌 제이. 스피겔 | 인돌유도체 |
| GB9201038D0 (en) * | 1992-01-16 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| AU686654B2 (en) * | 1993-08-31 | 1998-02-12 | Pfizer Inc. | 5-arylindole derivatives |
| GB9523999D0 (en) * | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
| HN1998000118A (es) * | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| CA2425185A1 (en) * | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
-
2001
- 2001-12-06 DE DE10159922A patent/DE10159922A1/de not_active Withdrawn
-
2002
- 2002-12-02 AT AT02798318T patent/ATE357441T1/de active
- 2002-12-02 WO PCT/EP2002/013613 patent/WO2003048156A1/de active IP Right Grant
- 2002-12-02 JP JP2003549346A patent/JP4663982B2/ja not_active Expired - Fee Related
- 2002-12-02 EP EP02798318A patent/EP1451177B1/de not_active Expired - Lifetime
- 2002-12-02 AU AU2002363859A patent/AU2002363859B2/en not_active Ceased
- 2002-12-02 DE DE50209798T patent/DE50209798D1/de not_active Expired - Lifetime
- 2002-12-02 DK DK02798318T patent/DK1451177T3/da active
- 2002-12-02 PL PL02371270A patent/PL371270A1/pl not_active IP Right Cessation
- 2002-12-02 MX MXPA04005139A patent/MXPA04005139A/es active IP Right Grant
- 2002-12-02 SI SI200230538T patent/SI1451177T1/sl unknown
- 2002-12-02 PT PT02798318T patent/PT1451177E/pt unknown
- 2002-12-02 CA CA2469346A patent/CA2469346C/en not_active Expired - Fee Related
- 2002-12-02 HU HU0402283A patent/HUP0402283A3/hu unknown
- 2002-12-02 ES ES02798318T patent/ES2284973T3/es not_active Expired - Lifetime
- 2002-12-04 PE PE2002001168A patent/PE20030748A1/es not_active Application Discontinuation
- 2002-12-05 AR ARP020104713A patent/AR037707A1/es unknown
-
2004
- 2004-06-07 US US10/861,426 patent/US7271192B2/en not_active Expired - Fee Related
-
2007
- 2007-05-10 CY CY20071100631T patent/CY1106576T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1451177E (pt) | 2007-04-30 |
| AR037707A1 (es) | 2004-12-01 |
| PE20030748A1 (es) | 2003-09-05 |
| ES2284973T3 (es) | 2007-11-16 |
| DE10159922A1 (de) | 2003-06-26 |
| AU2002363859A1 (en) | 2003-06-17 |
| HUP0402283A3 (en) | 2009-07-28 |
| CY1106576T1 (el) | 2012-01-25 |
| CA2469346C (en) | 2010-10-19 |
| MXPA04005139A (es) | 2004-08-11 |
| EP1451177B1 (de) | 2007-03-21 |
| EP1451177A1 (de) | 2004-09-01 |
| SI1451177T1 (sl) | 2007-08-31 |
| DK1451177T3 (da) | 2007-07-02 |
| HUP0402283A2 (hu) | 2005-02-28 |
| WO2003048156A1 (de) | 2003-06-12 |
| AU2002363859B2 (en) | 2008-09-18 |
| JP4663982B2 (ja) | 2011-04-06 |
| ATE357441T1 (de) | 2007-04-15 |
| US20050014815A1 (en) | 2005-01-20 |
| JP2005511694A (ja) | 2005-04-28 |
| US7271192B2 (en) | 2007-09-18 |
| DE50209798D1 (de) | 2007-05-03 |
| CA2469346A1 (en) | 2003-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208446A1 (en) | Derivatives of uk-2a uk-2a | |
| AU2002364300A8 (en) | Polymer derivatives for the treatment of metals | |
| IL209842A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
| HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| AU2001272852A1 (en) | Composition for the treatment of migraine | |
| PL376454A1 (pl) | Pochodne 1-acylo-pirolidynowe do leczenia zakażeńwirusowych | |
| IL162485A0 (en) | Compounds for the treatment of inflammatory disorders | |
| EP1442062A4 (en) | METHOD FOR TREATING CARCINOMA | |
| AU2003258145A8 (en) | Substituted phenylindoles for the treatment of hiv | |
| HUP0302739A3 (en) | Method for the treatment of tobacco | |
| IL136960A0 (en) | Combination therapy for the treatment of migraine | |
| IL160043A0 (en) | Process for the preparation of indole derivatives | |
| HUP0401600A3 (en) | Process for the preparation of 14-hydroxymorphine derivatives | |
| HUP0303443A3 (en) | Process for the preparation of imidazole derivatives | |
| AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
| EP1461030A4 (en) | AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| AU2002364711A8 (en) | Substituted 5-hydroxy-indole compounds for the treatment of glaucoma | |
| AU2001285156A1 (en) | Combination therapy for the treatment of migraine | |
| IL165137A0 (en) | Process for the preparation of thioalkylamine derivatives | |
| HK1059782A1 (en) | Indole derivatives useful for the treatment of cnsdisorders | |
| PT1451177E (pt) | Derivados substituídos de 2-pirrolidin-2-1l-1h-indole para o tratamento da enxaqueca. | |
| HU0001891D0 (en) | Medicament for the treatment of migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VOID | Decisions declaring the decisions on the grant of the patent lapsed |